ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

SRPT Sarepta Therapeutics Inc New

131.40
0.77 (0.59%)
Pre Market
Last Updated: 13:39:11
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sarepta Therapeutics Inc New NASDAQ:SRPT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.77 0.59% 131.40 131.01 133.99 260 13:39:11

Sarepta Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

02/06/2022 1:30pm

GlobeNewswire Inc.


Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart


From May 2022 to May 2024

Click Here for more Sarepta Therapeutics Charts.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Tuesday June 14, 2022 at 10:00 a.m. P.T./ 1:00 p.m. E.T. The fireside chat will be held at the Terranea Resort, Rancho Palos Verdes, CA.

The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta’s website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta TherapeuticsSarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of InformationWe routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact: Ian Estepan, 617-274-4052iestepan@sarepta.com

Media Contact: Tracy Sorrentino, 617-301-8566tsorrentino@sarepta.com 

 

1 Year Sarepta Therapeutics Chart

1 Year Sarepta Therapeutics Chart

1 Month Sarepta Therapeutics Chart

1 Month Sarepta Therapeutics Chart

Your Recent History

Delayed Upgrade Clock